A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit

Autor: Parkinson Study Group QE3 Investigators, Beal, M Flint, Oakes, David, Shoulson, Ira, Henchcliffe, Claire, Galpern, Wendy R, Haas, Richard, Juncos, Jorge L, Nutt, John G, Voss, Tiffini Smith, Ravina, Bernard, Shults, Clifford M, Helles, Karen, Snively, Victoria, Lew, Mark F, Griebner, Brian, Watts, Arthur, Gao, Shan, Pourcher, Emmanuelle, Bond, Louisette, Kompoliti, Katie, Agarwal, Pinky, Sia, Cherissa, Jog, Mandar, Cole, Linda, Sultana, Munira, Kurlan, Roger, Richard, Irene, Deeley, Cheryl, Waters, Cheryl H, Figueroa, Angel, Arkun, Ani, Brodsky, Matthew, Ondo, William G, Hunter, Christine B, Jimenez-Shahed, Joohi, Palao, Alicia, Miyasaki, Janis M, So, Julie, Tetrud, James, Reys, Liza, Smith, Katharine, Singer, Carlos, Blenke, Anita, Russell, David S, Cotto, Candace, Friedman, Joseph H, Lannon, Margaret, Zhang, Lin, Drasby, Edward, Kumar, Rajeev, Subramanian, Thyagarajan, Ford, Donna Stuppy, Grimes, David A, Cote, Diane, Conway, Jennifer, Siderowf, Andrew D, Evatt, Marian Leslie, Sommerfeld, Barbara, Lieberman, Abraham N, Okun, Michael S, Rodriguez, Ramon L, Merritt, Stacy, Swartz, Camille Louise, Martin, WR Wayne, King, Pamela, Stover, Natividad, Guthrie, Stephanie, Watts, Ray L, Ahmed, Anwar, Fernandez, Hubert H, Winters, Adrienna, Mari, Zoltan, Dawson, Ted M, Dunlop, Becky, Feigin, Andrew S, Shannon, Barbara, Nirenberg, Melissa Jill, Ogg, Mattson, Ellias, Samuel A, Thomas, Cathi-Ann, Frei, Karen, Bodis-Wollner, Ivan, Glazman, Sofya, Mayer, Thomas, Hauser, Robert A, Pahwa, Rajesh, Langhammer, April, Ranawaya, Ranjit, Derwent, Lorelei, Sethi, Kapil D, Farrow, Buff, Prakash, Rajan, Litvan, Irene, Robinson, Annette, Sahay, Alok, Gartner, Maureen, Hinson, Vanessa K, Markind, Samuel, Pelikan, Melisa

Publikováno v: JAMA neurology, vol 71, iss 5

ImportanceCoenzyme Q10 (CoQ10), an antioxidant that supports mitochondrial function, has been shown in preclinical Parkinson disease (PD) models to reduce the loss of dopamine neurons, and was safe and well tolerated in early-phase human studies. A p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::16ccdf1f3d2094db00082e294f17bce1
https://escholarship.org/uc/item/1857b3t0

Dopamine agonists and the risk of valvular heart disease

Autor: Martin, WR Wayne

Publikováno v: Nature Clinical Practice Neurology; August 2007, Vol. 3 Issue: 8 p426-427, 2p